Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

KRAS Inhibitor Market Snapshot from 2024 to 2034

The KRAS inhibitor market was valued at US$ 108 million in 2023. During the forecast period, the market is expected to garner a 5.5% CAGR. By 2034, the gold metalized market is expected to reach a valuation of US$ 196 million.

Report Attribute Details
Estimated Market Value in 2023 US$ 108 million
Expected Market Value in 2024 US$ 115.2 million
Projected Forecast Value in 2034 US$ 196 million
Anticipated Growth Rate from 2024 to 2034 5.5%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Demand Analysis of KRAS Inhibitors

The market players in the global KRAS inhibitor market are aimed at developing investigational drug candidates for the mutant KRAS. A key player has developed MRTX1133 which is used for the inhibition of KRASG12D. This candidate holds a strong potential to be a first of its kind therapeutic.

The development of KRAS inhibitor based combination treatments presents an opportunity. Improved patient outcomes, increased tumor response rates, and synergistic benefits may result from combining KRAS inhibitors alongside other targeted treatments, immunotherapies, or traditional chemotherapeutic drugs.

Exploring and implementing these combination techniques might result in innovative therapy regimens with improved efficacy against KRAS-mutated tumors, addressing unmet medical needs and widening the therapeutic environment in oncology.

KRAS Inhibitor Market Historical Analysis from 2019 to 2023 vs. Forecast Outlook from 2024 to 2034

In 2019, the global KRAS inhibitor market was estimated to reach a valuation of US$ 81.8 million, according to a report from Future Market Insights. The KRAS inhibitor market witnessed significant growth, registering a CAGR of 7.20% during the historical period, 2019 to 2023.

Historical CAGR from 2019 to 2023 7.20%
Forecast CAGR from 2024 to 2034 5.5%

The development of covalent inhibitors that specifically target specific KRAS mutants is a significant development in the KRAS inhibitor market. Traditional inhibitors frequently fail to target KRAS due to its complex structure and dynamic activity.

Covalent inhibitors may provide improved selectivity and effectiveness by forming a solid, permanent connection with their target. With the potential to provide patients with KRAS-driven tumors with more effective treatment choices, these covalent inhibitors mark a substantial advancement in KRAS-targeted therapy.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Significant Drivers of the KRAS Inhibitor Market

Innovative Drug Delivery Technologies to Support Market Demand

The KRAS inhibitor market is being driven by the development of innovative medication delivery systems. These innovative delivery methods increase the bioavailability and targeted administration of KRAS inhibitors. This helps in boosting their effectiveness and lowering the possibility of negative side effects.

These advances, which overcome difficulties such as low solubility and quick clearance, pave the path for more effective KRAS inhibitor treatment, improving their clinical relevance and, eventually, aiding patients with KRAS-mutated malignancies.

Factors which can Challenge the Market Growth

Poor Bioavailability and Inactivity of Cancer Cells to Restrict the Market Growth

Few of the inhibitors have been proven to show poor bioavailability, which delays the absorption of drugs. For instance, ARS-853, one of the first KRAS inhibitors developed not only had a lower bioavailability but also a shorter metabolic plasma stability.

KRAS inhibitors can at times fail to target all the cancer cells at the same time. In such a situation, this can lead to proliferation of the cancer cells at a faster pace. Such factors can impede the market growth.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Comparative View of Adjacent Markets

In this section, analysis will be drawn among three relevant markets. These are the KRAS inhibitor Market, lung cancer therapeutics market and cancer diagnostics market.

Globally increasing cancer incidence rates, increased need for precision treatment, and developing biotechnology advancements are the main drivers of these markets. The growth of these markets is attributed to rising knowledge of early detection techniques, regulatory frameworks that are supportive, and increased research spending.

The constant development and adoption of innovative treatments and diagnostic technologies is fueled by the necessity to meet unmet medical requirements and enhance patient outcomes.

KRAS Inhibitor Market:

Market Name KRAS Inhibitor Market
CAGR from 2024 to 2034 5.5%
Growth Factor Increased research and development towards investing new candidates to combat the KRAS mutant proteins.
Future Opportunities Partnerships can be quite effective for the market players to grow regionally.

Lung Cancer Therapeutics Market:

Market Name Lung Cancer Therapeutics Market
CAGR from 2024 to 2034 13.5%
Growth Factor The demand for lung cancer therapeutics is being driven by the development of nanomedicine as a lung cancer therapy and the increasing number of approvals within the lung cancer treatments market.
Future Opportunities The lung cancer therapeutics market is expected to grow due to an increase in regulatory approvals and the adoption of modern treatments in Europe.

Cancer Diagnostics Market:

Market Name Cancer Diagnostics Market
CAGR from 2024 to 2034 8.5%
Growth Factor In developed countries, the market is expected to be driven in the upcoming years by increasing infrastructure for diagnostic laboratories.
Future Opportunities Future market development is anticipated to be driven by a rise in government initiatives as well as those of other private organizations to increase awareness about early cancer detection and prevention.

Category wise Insights

This section focuses on providing detailed analysis of two particular market segments for KRAS inhibitor, the dominant cancer type and the significant end user. The two main segments discussed below are the pancreatic cancer and cancer diagnostic centers.

KRAS Inhibitor is likely to be Widely Employed for Pancreatic Cancer Treatments

Cancer Type Pancreatic Cancer
CAGR from 2024 to 2034 5.3%

During the forecast period, the KRAS inhibitors are anticipated to be widely used for treating pancreatic cancer. Since KRAS mutations are present in almost 90% of pancreatic tumors, targeted medicines such as KRAS inhibitors provide a promising way to combat the illness.

These inhibitors have the ability to precisely target the abnormal signaling pathways caused by KRAS mutations, which may slow the development of tumors and increase patient survival rates. Their ability to effectively combat pancreatic cancers with KRAS mutations makes them an indispensable part of any therapy plans for pancreatic cancer in the future.

Cancer Diagnostic Centers will be the Dominant end User of KRAS Inhibitors

End User Cancer Diagnostic Centers
CAGR from 2024 to 2034 5.1%

During the forecast period, the cancer diagnostic center will be utilizing the KRAS inhibitors widely. KRAS inhibitors are being widely used in cancer diagnostic centers to precisely identify patients with KRAS mutations, allowing for customized treatment methods.

Early diagnosis of these mutations is made easier by including KRAS inhibitor testing into diagnostic processes. This helps with prognostication as well as treatment decision-making, which ultimately improves patient outcomes and raises the standard of cancer care.

Region wise Analysis

This section will go into detail on the KRAS inhibitor markets in a few key countries, including the United States, the United Kingdom, China, Japan and South Korea. This sector will lay emphasis on the various reasons that are propelling the growth of KRAS inhibitors in the below mentioned regions.

Countries Forecast CAGRs from 2024 to 2034
The United States 5.7%
The United Kingdom 6.5%
China 6.2%
Japan 7%
South Korea 6.9%

Robust Research in the Field of Mutant KRAS Proteins to Propel Growth

The United States KRAS inhibitor ecosystem is anticipated to gain a CAGR of 5.7% through 2034. For instance, researchers from AstraZeneca have discovered a new drug candidate, AZD4747, which shows promise in treating tumors with the KRAS G12C mutation.

This mutation limits the ability of the GTPase KRAS to hydrolyze GTP to the inactive GDP-bound state, resulting in the constitutive activation of downstream signaling pathways.

The AstraZeneca research team discovered AZD4747, a highly effective and selective KRAS G12C inhibitor, using a structure-based drug development approach. Drug potency, drug metabolism, and pharmacokinetics (DMPK) characteristics were all optimized for the drug candidate.

Agreements with Companies from other Regions to Enhance Demand

The KRAS inhibitor market in the United Kingdom is expected to expand with a 6.5% CAGR through 2034. The regional companies are forging partnerships with companies outside the United Kingdom to boost their oncology pipeline.

For instance, the United Kingdom based Biotech Company RedX Pharma announced that it has entered an agreement with Jazz Pharmaceuticals, based out of Ireland. This was done to transfer the preclinical KRAS inhibitor program's global rights.

Under the conditions of the agreement, Redx Pharma will provide JAZZ an upfront payment of $10 million. This will be in return for all rights, patents, and interests pertaining to its exclusive KRAS inhibitor program, which includes its pan- and G12D-specific KRAS compounds.

Government Initiatives in China towards Better Healthcare to Propel Demand

The KRAS inhibitor ecosystem in China is anticipated to develop with a 6.2% CAGR from 2024 to 2034. As part of its wider healthcare reforms, the Chinese government has actively promoted and invested in the biotechnology and pharmaceutical industries.

The government's goals with the Made in China 2025 plan as well as the Healthy China 2030 policy are to solve healthcare issues and improve domestic innovation capacities.

Funding research and development in fields like cancer therapeutics, including KRAS inhibitors, is part of this. The development and marketing of KRAS inhibitors in China might be expedited by government financing, favorable policies, along with regulatory reforms.

Booming Pharmaceutical Sector in Japan to Push Demand for KRAS Inhibitor

The KRAS inhibitor industry in Japan is anticipated to reach a 7% CAGR from 2024 to 2034. Japan has a thriving pharmaceutical sector, with several major companies engaged in the research and development of new drugs.

These companies have an abundance of knowledge and resources devoted to cancer and other medicinal research and innovation. Japanese pharmaceutical companies are investing in the research and development of KRAS inhibitors as potential treatments for different cancers, with an emphasis on precision medicine and customized therapy.

Biotech Innovations in South Korea to Propel Demand

The South Korea KRAS inhibitor ecosystem is anticipated to expand with a 6.9% CAGR during the forecast period. The biotechnology sector in South Korea is expanding quickly, with a particular emphasis on developing innovative treatments for a range of diseases, including cancer.

The country boasts a robust biotech workforce with advanced skills and a robust research infrastructure. Investing in biotech firms and research institutes helps to discover new treatments, including KRAS inhibitors, which have the potential to cure malignancies caused by mutations in the KRAS gene.

Market Competition

Market players are experimenting with various kinds of KRAS inhibitors for better outcomes to treat cancer patients. Companies are drifting towards researching with two forms, KRASG12C inhibitor and KRASG12D Inhibitor.

For instance, Adagrasib, which Mirati is developing, is intended to specifically target the KRASG12C mutation and optimize inhibition by trapping the mutant protein in an irreversible state. Adagrasib is one of the company’s highly selective, investigational and potent oral small molecule therapy.

Preclinical research has demonstrated that adagrasib produced significantly stronger anti-tumor activity when combined with a wide variety of medicines, such as SHP2, PD-1, Pan-EGFR, CDK 4/6, and SOS1 inhibitors.

The objective of the market players is to maximize effectiveness and avoid treatment resistance. They also want to make sure that patients may benefit from these potentially helpful combination treatments for the duration of their therapy. The key players in this market include:

  • Amgen
  • Boehringer Ingelheim
  • BridgeBio Pharma
  • Erasca
  • Innovent Biologics Inc.
  • Incyte
  • Mirati Therapeutics
  • Novartis
  • Jemincare
  • Cardiff Oncology Inc.

Key Developments

  • In 2024, Amgen revealed new data from its CodeBreaK trial program at the ASCO Annual Meeting, emphasizing the effectiveness of LUMAKRAS®/LUMYKRAS® (sotorasib). The results were based on advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).
  • A major development in KRAS inhibitor therapy was demonstrated by the Amgen-funded SCARLET research. It demonstrated sotorasib's safety and effectiveness when combined with platinum-based chemotherapy for the frontline treatment of advanced NSCLC with a KRAS G12C mutation.

Key Coverage in KRAS Inhibitor Market Report

  • Oncology KRAS-targeting therapy market
  • Global Kirsten Rat Sarcoma (KRAS) Market
  • KRAS Inhibitor lung cancer
  • KRAS Inhibitor FDA approval

Report Scope

Report Attribute Details
Growth Rate CAGR of 5.5% from 2024 to 2034
Market value in 2024 US$ 115.2 million
Market value in 2034 US$ 196 million
Base Year for Estimation 2023
Historical Data 2019 to 2023
Forecast Period 2024 to 2034
Quantitative Units US$ million for value
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Cancer Type
  • End User
  • Region
Regions Covered
  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • South Asia and Pacific
  • East Asia
  • The Middle East & Africa
Countries Profiled
  • The United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • The United Kingdom
  • France
  • Spain
  • Italy
  • Poland
  • Russia
  • Czech Republic
  • Romania
  • India
  • Bangladesh
  • Australia
  • New Zealand
  • China
  • Japan
  • South Korea
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Amgen
  • Boehringer Ingelheim
  • BridgeBio Pharma
  • Erasca
  • Innovent Biologics Inc.
  • Incyte
  • Mirati Therapeutics
  • Novartis
  • Jemincare
  • Cardiff Oncology Inc.
Customisation Scope Available on Request

Key Segments Profiled in the KRAS Inhibitor Market

By Cancer Type:

  • Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • Others

By End User:

  • Clinic Laboratories
  • Cancer Diagnostic Centres
  • Hospitals
  • Cancer Research Institutes
  • Academic Institutions
  • Others

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • South Asia and Pacific
  • East Asia
  • The Middle East & Africa

Frequently Asked Questions

What is the anticipated growth rate of the KRAS inhibitor market from 2024 to 2034?

The KRAS inhibitor market is expected to garner a 5.5% CAGR from 2024 to 2034.

What will be the global market outlook for KRAS inhibitor through 2024?

By 2024, the global KRAS inhibitor market is likely to gain US$ 115.2 million.

What is the expected global market valuation for KRAS inhibitor by 2034?

By 2034, the KRAS inhibitor market valuation is likely to reach a sum of US$ 196 million.

How will the demand for KRAS inhibitors develop in the United States?

The KRAS inhibitor industry in the United States is likely to garner a 5.7% CAGR during the forecast period.

Which cancer type will use the KRAS inhibitor widely?

The KRAS inhibitor will be widely used for the treatment of pancreatic cancer, along with an anticipated 5.3% CAGR through 2034.

Which institution will be the dominant end user in the KRAS inhibitor market?

The cancer diagnostic centers are likely to be the dominant end users of the KRAS inhibitor, with an expected 5.1% CAGR through 2034.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034

    4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Cancer Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Cancer Type, 2019 to 2023

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Cancer Type, 2024 to 2034

        5.3.1. Lung Cancer

        5.3.2. Pancreatic Cancer

        5.3.3. Colorectal Cancer

        5.3.4. Others

    5.4. Y-o-Y Growth Trend Analysis By Cancer Type, 2019 to 2023

    5.5. Absolute $ Opportunity Analysis By Cancer Type, 2024 to 2034

6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-User

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2019 to 2023

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2024 to 2034

        6.3.1. Clinic Laboratories

        6.3.2. Cancer Diagnostic Centres

        6.3.3. Hospitals

        6.3.4. Cancer Research Institutes

        6.3.5. Academic Institutions

        6.3.6. Others

    6.4. Y-o-Y Growth Trend Analysis By End-User, 2019 to 2023

    6.5. Absolute $ Opportunity Analysis By End-User, 2024 to 2034

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Western Europe

        7.3.4. Eastern Europe

        7.3.5. South Asia and Pacific

        7.3.6. East Asia

        7.3.7. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Cancer Type

        8.2.3. By End-User

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Cancer Type

        8.3.3. By End-User

    8.4. Key Takeaways

9. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Cancer Type

        9.2.3. By End-User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Cancer Type

        9.3.3. By End-User

    9.4. Key Takeaways

10. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. UK

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Western Europe

        10.2.2. By Cancer Type

        10.2.3. By End-User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Cancer Type

        10.3.3. By End-User

    10.4. Key Takeaways

11. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        11.2.1. By Country

            11.2.1.1. Poland

            11.2.1.2. Russia

            11.2.1.3. Czech Republic

            11.2.1.4. Romania

            11.2.1.5. Rest of Eastern Europe

        11.2.2. By Cancer Type

        11.2.3. By End-User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Cancer Type

        11.3.3. By End-User

    11.4. Key Takeaways

12. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Bangladesh

            12.2.1.3. Australia

            12.2.1.4. New Zealand

            12.2.1.5. Rest of South Asia and Pacific

        12.2.2. By Cancer Type

        12.2.3. By End-User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Cancer Type

        12.3.3. By End-User

    12.4. Key Takeaways

13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Cancer Type

        13.2.3. By End-User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Cancer Type

        13.3.3. By End-User

    13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Cancer Type

        14.2.3. By End-User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Cancer Type

        14.3.3. By End-User

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Market Share Analysis, 2023

            15.1.1.1. By Cancer Type

            15.1.1.2. By End-User

    15.2. Canada

        15.2.1. Market Share Analysis, 2023

            15.2.1.1. By Cancer Type

            15.2.1.2. By End-User

    15.3. Brazil

        15.3.1. Market Share Analysis, 2023

            15.3.1.1. By Cancer Type

            15.3.1.2. By End-User

    15.4. Mexico

        15.4.1. Market Share Analysis, 2023

            15.4.1.1. By Cancer Type

            15.4.1.2. By End-User

    15.5. Germany

        15.5.1. Market Share Analysis, 2023

            15.5.1.1. By Cancer Type

            15.5.1.2. By End-User

    15.6. UK

        15.6.1. Market Share Analysis, 2023

            15.6.1.1. By Cancer Type

            15.6.1.2. By End-User

    15.7. France

        15.7.1. Market Share Analysis, 2023

            15.7.1.1. By Cancer Type

            15.7.1.2. By End-User

    15.8. Spain

        15.8.1. Market Share Analysis, 2023

            15.8.1.1. By Cancer Type

            15.8.1.2. By End-User

    15.9. Italy

        15.9.1. Market Share Analysis, 2023

            15.9.1.1. By Cancer Type

            15.9.1.2. By End-User

    15.10. Poland

        15.10.1. Market Share Analysis, 2023

            15.10.1.1. By Cancer Type

            15.10.1.2. By End-User

    15.11. Russia

        15.11.1. Market Share Analysis, 2023

            15.11.1.1. By Cancer Type

            15.11.1.2. By End-User

    15.12. Czech Republic

        15.12.1. Market Share Analysis, 2023

            15.12.1.1. By Cancer Type

            15.12.1.2. By End-User

    15.13. Romania

        15.13.1. Market Share Analysis, 2023

            15.13.1.1. By Cancer Type

            15.13.1.2. By End-User

    15.14. India

        15.14.1. Market Share Analysis, 2023

            15.14.1.1. By Cancer Type

            15.14.1.2. By End-User

    15.15. Bangladesh

        15.15.1. Market Share Analysis, 2023

            15.15.1.1. By Cancer Type

            15.15.1.2. By End-User

    15.16. Australia

        15.16.1. Market Share Analysis, 2023

            15.16.1.1. By Cancer Type

            15.16.1.2. By End-User

    15.17. New Zealand

        15.17.1. Market Share Analysis, 2023

            15.17.1.1. By Cancer Type

            15.17.1.2. By End-User

    15.18. China

        15.18.1. Market Share Analysis, 2023

            15.18.1.1. By Cancer Type

            15.18.1.2. By End-User

    15.19. Japan

        15.19.1. Market Share Analysis, 2023

            15.19.1.1. By Cancer Type

            15.19.1.2. By End-User

    15.20. South Korea

        15.20.1. Market Share Analysis, 2023

            15.20.1.1. By Cancer Type

            15.20.1.2. By End-User

    15.21. GCC Countries

        15.21.1. Market Share Analysis, 2023

            15.21.1.1. By Cancer Type

            15.21.1.2. By End-User

    15.22. South Africa

        15.22.1. Market Share Analysis, 2023

            15.22.1.1. By Cancer Type

            15.22.1.2. By End-User

    15.23. Israel

        15.23.1. Market Share Analysis, 2023

            15.23.1.1. By Cancer Type

            15.23.1.2. By End-User

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Cancer Type

        16.3.3. By End-User

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Amgen

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Boehringer Ingelheim

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. BridgeBio Pharma

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Erasca

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Innovent Biologics, Inc.

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Incyte

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Mirati Therapeutics

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Novartis

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Jemincare

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Cardiff Oncology, Inc.

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034

Table 2: Global Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034

Table 3: Global Market Value (US$ Million) Forecast by End-User, 2019 to 2034

Table 4: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034

Table 5: North America Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034

Table 6: North America Market Value (US$ Million) Forecast by End-User, 2019 to 2034

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034

Table 8: Latin America Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034

Table 9: Latin America Market Value (US$ Million) Forecast by End-User, 2019 to 2034

Table 10: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034

Table 11: Western Europe Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034

Table 12: Western Europe Market Value (US$ Million) Forecast by End-User, 2019 to 2034

Table 13: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034

Table 14: Eastern Europe Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034

Table 15: Eastern Europe Market Value (US$ Million) Forecast by End-User, 2019 to 2034

Table 16: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034

Table 17: South Asia and Pacific Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034

Table 18: South Asia and Pacific Market Value (US$ Million) Forecast by End-User, 2019 to 2034

Table 19: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034

Table 20: East Asia Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034

Table 21: East Asia Market Value (US$ Million) Forecast by End-User, 2019 to 2034

Table 22: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034

Table 23: Middle East and Africa Market Value (US$ Million) Forecast by Cancer Type, 2019 to 2034

Table 24: Middle East and Africa Market Value (US$ Million) Forecast by End-User, 2019 to 2034
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Cancer Type, 2024 to 2034

Figure 2: Global Market Value (US$ Million) by End-User, 2024 to 2034

Figure 3: Global Market Value (US$ Million) by Region, 2024 to 2034

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034

Figure 7: Global Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034

Figure 8: Global Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034

Figure 9: Global Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034

Figure 10: Global Market Value (US$ Million) Analysis by End-User, 2019 to 2034

Figure 11: Global Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034

Figure 12: Global Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034

Figure 13: Global Market Attractiveness by Cancer Type, 2024 to 2034

Figure 14: Global Market Attractiveness by End-User, 2024 to 2034

Figure 15: Global Market Attractiveness by Region, 2024 to 2034

Figure 16: North America Market Value (US$ Million) by Cancer Type, 2024 to 2034

Figure 17: North America Market Value (US$ Million) by End-User, 2024 to 2034

Figure 18: North America Market Value (US$ Million) by Country, 2024 to 2034

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034

Figure 22: North America Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034

Figure 23: North America Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034

Figure 24: North America Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034

Figure 25: North America Market Value (US$ Million) Analysis by End-User, 2019 to 2034

Figure 26: North America Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034

Figure 27: North America Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034

Figure 28: North America Market Attractiveness by Cancer Type, 2024 to 2034

Figure 29: North America Market Attractiveness by End-User, 2024 to 2034

Figure 30: North America Market Attractiveness by Country, 2024 to 2034

Figure 31: Latin America Market Value (US$ Million) by Cancer Type, 2024 to 2034

Figure 32: Latin America Market Value (US$ Million) by End-User, 2024 to 2034

Figure 33: Latin America Market Value (US$ Million) by Country, 2024 to 2034

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034

Figure 37: Latin America Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034

Figure 40: Latin America Market Value (US$ Million) Analysis by End-User, 2019 to 2034

Figure 41: Latin America Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034

Figure 43: Latin America Market Attractiveness by Cancer Type, 2024 to 2034

Figure 44: Latin America Market Attractiveness by End-User, 2024 to 2034

Figure 45: Latin America Market Attractiveness by Country, 2024 to 2034

Figure 46: Western Europe Market Value (US$ Million) by Cancer Type, 2024 to 2034

Figure 47: Western Europe Market Value (US$ Million) by End-User, 2024 to 2034

Figure 48: Western Europe Market Value (US$ Million) by Country, 2024 to 2034

Figure 49: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034

Figure 50: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034

Figure 51: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034

Figure 52: Western Europe Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034

Figure 53: Western Europe Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034

Figure 54: Western Europe Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034

Figure 55: Western Europe Market Value (US$ Million) Analysis by End-User, 2019 to 2034

Figure 56: Western Europe Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034

Figure 57: Western Europe Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034

Figure 58: Western Europe Market Attractiveness by Cancer Type, 2024 to 2034

Figure 59: Western Europe Market Attractiveness by End-User, 2024 to 2034

Figure 60: Western Europe Market Attractiveness by Country, 2024 to 2034

Figure 61: Eastern Europe Market Value (US$ Million) by Cancer Type, 2024 to 2034

Figure 62: Eastern Europe Market Value (US$ Million) by End-User, 2024 to 2034

Figure 63: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034

Figure 64: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034

Figure 65: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034

Figure 66: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034

Figure 67: Eastern Europe Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034

Figure 68: Eastern Europe Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034

Figure 69: Eastern Europe Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034

Figure 70: Eastern Europe Market Value (US$ Million) Analysis by End-User, 2019 to 2034

Figure 71: Eastern Europe Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034

Figure 72: Eastern Europe Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034

Figure 73: Eastern Europe Market Attractiveness by Cancer Type, 2024 to 2034

Figure 74: Eastern Europe Market Attractiveness by End-User, 2024 to 2034

Figure 75: Eastern Europe Market Attractiveness by Country, 2024 to 2034

Figure 76: South Asia and Pacific Market Value (US$ Million) by Cancer Type, 2024 to 2034

Figure 77: South Asia and Pacific Market Value (US$ Million) by End-User, 2024 to 2034

Figure 78: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034

Figure 79: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034

Figure 80: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034

Figure 81: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034

Figure 82: South Asia and Pacific Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034

Figure 83: South Asia and Pacific Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034

Figure 84: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034

Figure 85: South Asia and Pacific Market Value (US$ Million) Analysis by End-User, 2019 to 2034

Figure 86: South Asia and Pacific Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034

Figure 87: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034

Figure 88: South Asia and Pacific Market Attractiveness by Cancer Type, 2024 to 2034

Figure 89: South Asia and Pacific Market Attractiveness by End-User, 2024 to 2034

Figure 90: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034

Figure 91: East Asia Market Value (US$ Million) by Cancer Type, 2024 to 2034

Figure 92: East Asia Market Value (US$ Million) by End-User, 2024 to 2034

Figure 93: East Asia Market Value (US$ Million) by Country, 2024 to 2034

Figure 94: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034

Figure 95: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034

Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034

Figure 97: East Asia Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034

Figure 98: East Asia Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034

Figure 99: East Asia Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034

Figure 100: East Asia Market Value (US$ Million) Analysis by End-User, 2019 to 2034

Figure 101: East Asia Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034

Figure 102: East Asia Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034

Figure 103: East Asia Market Attractiveness by Cancer Type, 2024 to 2034

Figure 104: East Asia Market Attractiveness by End-User, 2024 to 2034

Figure 105: East Asia Market Attractiveness by Country, 2024 to 2034

Figure 106: Middle East and Africa Market Value (US$ Million) by Cancer Type, 2024 to 2034

Figure 107: Middle East and Africa Market Value (US$ Million) by End-User, 2024 to 2034

Figure 108: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034

Figure 109: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034

Figure 110: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034

Figure 111: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034

Figure 112: Middle East and Africa Market Value (US$ Million) Analysis by Cancer Type, 2019 to 2034

Figure 113: Middle East and Africa Market Value Share (%) and BPS Analysis by Cancer Type, 2024 to 2034

Figure 114: Middle East and Africa Market Y-o-Y Growth (%) Projections by Cancer Type, 2024 to 2034

Figure 115: Middle East and Africa Market Value (US$ Million) Analysis by End-User, 2019 to 2034

Figure 116: Middle East and Africa Market Value Share (%) and BPS Analysis by End-User, 2024 to 2034

Figure 117: Middle East and Africa Market Y-o-Y Growth (%) Projections by End-User, 2024 to 2034

Figure 118: Middle East and Africa Market Attractiveness by Cancer Type, 2024 to 2034

Figure 119: Middle East and Africa Market Attractiveness by End-User, 2024 to 2034

Figure 120: Middle East and Africa Market Attractiveness by Country, 2024 to 2034

Recommendations

Healthcare

Cancer Diagnostics Market

Published : August 2023

Healthcare

Cancer Biological Therapy Market

Published : December 2022

Healthcare

Kinase Inhibitors For Cancer Treatment Market

Published : November 2022

Healthcare

Lung Cancer Therapeutics Market

Published : June 2022

Explore Healthcare Insights

View Reports